BIO.DEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:36):

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments...

Stats
本日の出来高	100.00
平均出来高	154.00
時価総額	1.40B
EPS	€0 ( 2024-03-28 )
次の収益日	( €0 ) 2024-05-06
Last Dividend	€0.0400 ( 2019-05-08 )
Next Dividend	€0 ( N/A )
P/E	13.00
ATR14	€0 (0.00%)

Biotest AG 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Biotest AG 財務諸表

Annual	2023
収益:	€684.60M
総利益:	€271.90M (39.72 %)
EPS:	€3.21

FY	2023
収益:	€684.60M
総利益:	€271.90M (39.72 %)
EPS:	€3.21

FY	2022
収益:	€516.10M
総利益:	€124.90M (24.20 %)
EPS:	€-0.800

FY	2021
収益:	€515.60M
総利益:	€80.70M (15.65 %)
EPS:	€-1.610

Financial Reports:

No articles found.

Biotest AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Biotest AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.59 - good (75.92%) | Divividend Growth Potential Score: 1.201 - No dividend growth expected in the near future

Information

First Dividend	€0.0667	2000-07-17
Last Dividend	€0.0400	2019-05-08
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	€1.683	--
Avg. Dividend % Per Year	0.00%	--
Score	2	--
Div. Sustainability Score	7.59
Div.Growth Potential Score	1.201
Div. Directional Score	4.40	--

Next Divdend (Est)
(2024-12-30)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NVJP.DE	Ex Dividend Knight	2023-08-18	Annually	0.00%
AHC.DE	Ex Dividend Knight	2023-09-15	Quarterly	0.00%
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
PUM.DE	Ex Dividend Junior	2023-05-25	Annually	0.00%
BMW.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
INN1.DE	Ex Dividend Junior	2023-08-07	Semi-Annually	0.00%
SWF.DE	Ex Dividend Junior	2023-09-01	Quarterly	0.00%
CVS.DE	Ex Dividend Knight	2023-10-19	Quarterly	0.00%
LUS1.DE	Ex Dividend Junior	2023-06-23	Annually	0.00%
2M6.DE	Ex Dividend Knight	2023-09-21	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.217	1.500	5.65	8.48	[0 - 0.5]
returnOnAssetsTTM	0.107	1.200	6.43	7.71	[0 - 0.3]
returnOnEquityTTM	0.368	1.500	7.02	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.963	0.800	5.18	4.15	[1 - 3]
quickRatioTTM	0.845	0.800	9.74	7.79	[0.8 - 2.5]
cashRatioTTM	0.308	1.500	9.40	10.00	[0.2 - 2]
debtRatioTTM	0.441	-1.500	2.64	-3.97	[0 - 0.6]
interestCoverageTTM	4.47	1.000	9.46	9.46	[3 - 30]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
freeCashFlowPerShareTTM	-0.884	2.00	-0.442	-0.884	[0 - 20]
debtEquityRatioTTM	1.278	-1.500	4.89	-7.33	[0 - 2.5]
grossProfitMarginTTM	0.432	1.000	6.13	6.13	[0.2 - 0.8]
operatingProfitMarginTTM	0.251	1.000	6.98	6.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00251	1.000	-1.125	-1.125	[0.2 - 2]
assetTurnoverTTM	0.493	0.800	-0.0455	-0.0364	[0.5 - 2]
Total Score				7.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.63	1.000	9.03	0	[1 - 100]
returnOnEquityTTM	0.368	2.50	8.09	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.884	2.00	-0.295	-0.884	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.115	1.500	-2.57	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00225	1.000	-2.56	0	[0.1 - 0.5]
Total Score				1.201

Biotest AG

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.